Norcantharidin inhibits the malignant progression of cervical cancer by inducing endoplasmic reticulum stress

Mol Med Rep. 2024 May;29(5):71. doi: 10.3892/mmr.2024.13195. Epub 2024 Mar 8.

Abstract

The antitumor effect of norcantharidin (NCTD) has been widely reported. However, whether NCTD can inhibit cervical cancer remains unknown. In the present study, it was shown that NCTD inhibited the viability of cervical cancer cells and caused cell cycle arrest in a concentration‑dependent manner. Further analysis revealed that the NCTD‑induced reduction in cell viability could be reversed by the inhibitor of apoptosis z‑VAD‑FMK and by the inhibitor of endoplasmic reticulum (ER) stress, 4‑phenylbutyric acid (4‑PBA). Additionally, NCTD led to the accumulation of reactive oxygen species as well as a decrease in the mitochondrial membrane potential in cervical cancer cells, whereas 4‑PBA pre‑treatment attenuated these alterations. In addition, NCTD increased the expression of the apoptosis‑related proteins Bip, activating transcription factor (ATF) 4 and C/EBP homologous protein in a concentration‑dependent manner. Moreover, NCTD significantly increased the expression of the ER stress‑related signaling molecules protein kinase R‑like ER kinase, inositol‑requiring enzyme 1 and ATF6, but 4‑PBA abolished these effects. In vivo experiments showed that NCTD significantly inhibited the growth of subcutaneous tumors in mice. Additionally, the expression of ER stress‑related molecules and apoptosis‑related proteins increased significantly after NCTD treatment. In conclusion, NCTD induces apoptosis by activating ER stress and ultimately curtails the progression of cervical cancer.

Keywords: apoptosis; cervical cancer; endoplasmic reticulum stress; norcantharidin.

MeSH terms

  • Animals
  • Apoptosis
  • Bridged Bicyclo Compounds, Heterocyclic*
  • Butylamines*
  • Cell Line, Tumor
  • Cell Proliferation
  • Endoplasmic Reticulum Stress
  • Female
  • Humans
  • Mice
  • Uterine Cervical Neoplasms* / drug therapy

Substances

  • 4-phenylbutylamine
  • norcantharidin
  • Butylamines
  • Bridged Bicyclo Compounds, Heterocyclic

Grants and funding

This work was supported by Natural Science Foundation of Inner Mongolia Autonomous Region (grant no. 2019BS08001).